Marker predicts response to breast cancer drug Taxol
This article was originally published in Clinica
Executive Summary
Patients whose breast cancer cells have lost their ability to express a protein called tau are twice as likely to have a good response to therapy with Taxol, a drug commonly used to treat stage I-III breast cancers.